In ovarian cancer, cells that exhibit resistant to platinum-based chemotherapeutic drugs tend to express lower levels of GPC3, suggesting a negative regulatory role for GPC3 in the development of drug resistance [105]. The gene discussed is GPC3; the disease is ovarian carcinoma.